ReviewOncogene2003
Drug methylation in cancer therapy: lessons from the TPMT polymorphism.
Review in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update.Clinical pharmacology and therapeutics · 2013Guideline
- Structural and Functional Disruption of Thiopurine S‑Methyltransferase by the A80P Variant: A Simulation and Genotyping Study.ACS omega · 2026Article
- METTL7A (TMT1A) and METTL7B (TMT1B) Are Responsible for AlkylDrug metabolism and disposition: the biological fate of chemicals · 2023Article
- Gut Microbiota Metabolism of Azathioprine: A New Hallmark for Personalized Drug-Targeted Therapy of Chronic Inflammatory Bowel Disease.Frontiers in pharmacology · 2022Review
- TPMT mRNA Expression: A Novel Prognostic Biomarker for Patients with Colon Cancer by Bioinformatics Analysis.International journal of general medicine · 2022Article
- Microbiota and Drug Response in Inflammatory Bowel Disease.Pathogens (Basel, Switzerland) · 2021Review
- Sources of Interindividual Variability.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Pharmacogenetics implementation in the clinics: information and guidelines for germline variants.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells.Molecular oncology · 2018Article
- High frequency of mutant thiopurine S-methyltransferase genotypes in Mexican patients with systemic lupus erythematosus and rheumatoid arthritis.Clinical rheumatology · 2018Article
- Genetic Polymorphism of Thiopurine S-methyltransferase in Children with Acute Lymphoblastic Leukemia in JordanAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Thiopurine-induced mitotic catastrophe in Rad51d-deficient mammalian cells.Environmental and molecular mutagenesis · 2018Article
- Mirror, mirror on the wall: which microbiomes will help heal them all?BMC medicine · 2016Article
- Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.The pharmacogenomics journal · 2015Article
- Identification of cellular proteome using two-dimensional difference gel electrophoresis in ST cells infected with transmissible gastroenteritis coronavirus.Proteome science · 2013Article
- PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.Human molecular genetics · 2012Article
- Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Biomarkers in medicine · 2012Review
- Cancer pharmacogenomics.Clinical pharmacology and therapeutics · 2011Review
- Pharmacogenomics in pediatric leukemia.Current opinion in pediatrics · 2010Review
- Very important pharmacogene summary: thiopurine S-methyltransferase.Pharmacogenetics and genomics · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The genetic polymorphism of thiopurine methyltransferase (TPMT) is one of the most developed examples of pharmacogenetics, spanning from molecular genetics to clinical diagnostics for individualizing thiopurine therapy (i.e. azathioprine, mercaptopurine, and thioguanine). Elucidation of the molecular mechanisms and biochemical consequences of TPMT deficiency demonstrates how pharmacogenetic traits can be identified, characterized, and translated to the bedside. Insights gained from studies of the TPMT polymorphism illustrate the potential of pharmacogenomics to optimize cancer therapy by avoiding toxic side effects in genetically distinct subgroups of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.